ABSTRACT Exosomes are small-sized extracellular vesicles that are released by many cell types and can be found in different bodily fluids. Exosomes have attracted significant attention over the past decades as they contain biomolecules with a similar profile to their cell of origin that can be used in identifying normal and pathological cell states, such as lipids, nucleic acids, and proteins. Therefore, exosomes are being valued over their diagnostic and therapeutic utilities and their potential as novel drug delivery vehicles. Despite their usefulness, exosomes are approximately 30-200 nm and can vary in contents and compositions, thus making the separation and detection of them extremely challenging. Current exosome isolation and detection techniques are limited by low yield, low purity, requiring cumbersome instruments, and relatively long processing time. However, recent advancements of microfluidics technologies offered new exosome isolation and detection techniques with the great potential to overcome these limitations. Here, we compiled a thorough review that includes latest works on using microfluidic technologies to isolate and detect exosomes in different bodily fluids and comments on their advantages and disadvantages, with the hope to identify future research opportunities and direction in the field.
I. INTRODUCTION
Extracellular vesicles (EVs) are a heterogeneous collection of membrane-bound carriers with complex cargoes including proteins, lipids, miRNAs and nucleic acids [1] , [2] . The most important property of EVs is that the cargoes that are released by most, if not all, cell types [3] , directly come from the origin of these cells. Therefore, they represent an important mode of intercellular communication by serving as vehicles for transferring between the cargos and their original hosts [2] , [4] . EVs include exosomes, activation-or apoptosis-induced microvesicles (MVs)/microparticles and apoptotic bodies [5] . Out of these available vesicles, exosomes, named by Rose Johnstone, are one of the smaller EVs
The associate editor coordinating the review of this manuscript and approving it for publication was Qilian Liang. that are 30-150 nm in size and are released through multivesicular bodies in the endosomal pathway ( Figure. 1 ) [6] . First came to attention at 1981, exosomes was identified as exfoliated vesicles with 5'-nucleotidase activity from the cultures of normal and neoplastic cell lines [7] . Then, transferring receptors were found within the sub-micrometer vesicles released during the in vitro maturation of sheep reticulocytes [8] , signifying the migration of internal vesicles to an extracellular environment. But it was not until the early 2000 did the scientists start to understand the specific functions behind the seemingly wandering vesicles secreted from their hosts. A decade later, exosomes are now more and more valued not only because of their potential diagnostic and therapeutic relevance, but also their utility as novel drug delivery vehicles [5] , [9] . Therefore, it is of great importance that one or more effective exosome isolation and detection methods are available for clinical application involving exosomes [10] . Nevertheless, due to the size and content variations of exosomes, their current isolation and detection techniques have limitations including low yield, low purity, require cumbersome instruments and prolonged processing time [11] , [12] . However, recent advancements of microfluidic technologies offered new exosome isolation and detection techniques with great potential to overcome these limitations.
Here, in this review, we first briefly summarize the conventional exosomes isolation, detection methods and then review the latest work on using microfluidic technologies to isolate and detect exosomes in different bodily fluids. By discussing the merits and limitations of each work, we hope to shed some light on the future research areas of exosome isolation and detection. Although a few reviews have been done on this subject [13] - [16] , most of the existing reviews did not consider the applicability of the isolation\detection techniques in different bodily fluids (i.e. serum, plasma, urine). Therefore, this review provides a fresh perspective as exosome isolation and detection methods are compartmentalized according to their applicability in different bodily fluids. In this way, the performance of each isolation and detection method can be easily compared among themselves. In addition, as a field in its infancy, the advancements progress rapidly, it is then of great importance to be able to keep track of the latest achievements in a timely manner.
II. APPLICATION OF EXOSOME RESEARCH
The most important reason for exosomes to attract significant attention is that they are now known to represent a new type of intercellular communication. This means exosomes can transfer their contents from donor cells to recipient cells during various physiological and pathological conditions [17] . Since exosome cargo contains information on cell subproteome, they can either be used as a source of disease biomarkers and drug delivery vehivles [18] .
A. EXOSOME AS A SOURCE OF DISEASE BIOMARKERS
Biomarkers can be used for the identification of normal biological processes, pathological developments, or pharmacological response to a therapeutic intervention [19] . Because exosomes participate closely in different pathological process developments, their role as a source of biomarkers for disease diagnostics has been valued more than ever before. Exosomes are known to associate with a variety of pathological conditions such as urinary exosomes contain cargoes secreted by cells from all nephron segments that can identify renal dysfunction and structural injury [19] , [20] ; exosomes present in maternal circulations contain miRNA may be of diagnostic values for early identification of preeclampsia [21] ; exosomal amyloid peptides accumulate in the brain plaques of Alzheimer's disease [22] ; fetal exosomes that present in amniotic fluid may potentially be used in early prenatal diagnostics [23] and most importantly, the surface of an exosome contains specific biomarkers, such as cluster of differentiation CD9, CD63, and CD81, and tumor susceptibility gene (TSG)101, which can be used for cancer diagnosis. Moreover, exosomes contains cancer patient-specific genes that allow personalized chemotherapy [13] . Compared with conventional biomarkers found in blood, exosomal biomarkers are more accessible from biofluids such as saliva, sweat, or urine, and have demonstrate comparable, in some cases even superior target specificity [24] - [26] .
B. EXOSOME AS VEHICLES FOR TARGETED DRUG DELIVERY
Besides serving as a source of biomarkers, exosomes have also displayed potential to be used as personalized targeted drug delivery vehicles [27] - [30] . Compared with other established liposome formulations and nanocarriers, exosomes, sometimes referred as natural liposomes, are comprised of natural lipid bilayers that adheres with their protein cargos that readily interact with cellular membranes [31] . Also, because exosomes are derived from a patient's own cells, they are far less likely to exert toxicity and are less immunogenic than any foreign delivery vehicle, drastically improving the drug therapeutic efficacy [28] . Finally, exosomes have the ability to cross biological barriers such as extravasation through vessel fenestrations, passage through the extracellular matrix [30] , and cross the blood-brain barrier [29] .
Giving the advantages, exosomes were thoroughly investigated as drug delivery vehicles in many cases. Specifically, Exosomal-based delivery system was developed for loading catalase into exosomes that potentially can be used to treat inflammatory and neurodegenerative disorders [28] . Moreover, exosomes released from mesenchymal stem cells produced significant cardio-protective paracrine effects against myocardial ischemia/reperfusion injury even without any drug loaded [32] . Also, chemotherapeutic drugs such as methotrexate can be loaded onto exosomes to inhibit tumor growth in murine cancer models [33] , and paclitaxel loaded on macrophage-derived exosomes showed high anticancer efficacy in a mouse model of pulmonary metastases [34] . The list goes on, overall, these works indicate that exosomes may represent a promising novel delivery platform for therapeutic agents of many different pathological conditions.
Despite the wide spread potential applications of exosomes, the practical relevance of using exosomes for clinical purposes is still rather limited. The most important reason is that the majority, if not all, exosome applications require isolation and extraction of a pure population of exosomes. However, factors such as contamination with non-exosomal proteins and other EV subtypes can lead to spurious identification of biomarkers and false conclusions of exosome biological activities [35] . Therefore, ideal exosome isolation techniques should be highly specific, preferably label-free to avoid contamination during downstream analysis, and support high-throughput operation [36] . 
III. CONVENTIONAL EXOSOMES ISOLATION AND ANALYSIS TECHNIQUES

A. CONVENTIONAL EXOSOME ISOLATION METHODS
Currently, many techniques have been developed for exosomes isolation, including but not limited to centrifugation, precipitation, Immunoaffinity capture, ultrafiltration and size exclusion chromatography. Some of the methods have commercially isolation kit available. Since these methods have been thoroughly discussed in previous literatures, we only shall briefly state each of the techniques in the following section.
1) CENTRIFUGATION
Centrifugation relies on the different size and densities of the particles in a multicomponent mixer to sediment at different rates. It does not require technical expertise or complicated sample pretreatment steps. Due to these benefits, centrifugation-based techniques such as differential centrifugation and ultracentrifugation are the most commonly used methods to extract nanosized vesicles from cell culture media and bodily fluids. They are considered as the gold standard for exosome isolation [37] . It is estimated that centrifugation accounts for 56% of all exosome isolation techniques employed by users in exosome research [38] . However, centrifugation-based methods are rather time-consuming and often require the use of sophisticated commercial instruments. Also, if the sedimentation properties of the particles are similar, which is the case for different types of EVs [1] , the yield efficiency [39] as well as the purity of the isolated exosome population [40] are rather unsatisfactory.
2) SIZE EXCLUSION CHROMATOGRAPHY (SEC)
SEC method is a sized-based separation technique. In SEC, a porous stationary phase is used to separate particles according to their size. Particles in a sample mixture with small hydrodynamic radii are able to pass through the pores and particles as radii larger than the pores are kept from entering the pores [41] . SEC has been reported to produce satisfactory results in term of purity for isolating exosomes in blood plasma [42] . However, the yield efficiency for the SEC method is still up for debate. There are commercial isolation kits available basing on the SEC method, such as qEV TM (Izon Science, Christchurch, New Zealand). In addition, SEC method can be combined with other isolation methods such as precipitation (Exo-spin TM , Cell Guidance Systems LLC, St. Louis, USA) to improve the yield and purity.
Another popular sized based isolation technique is ultrafiltration. Similar to the conventional membrane filtration, exosomes can be isolated using membrane filters with predetermined pore size and pore density. Ultrafiltration is particularly useful for isolating exosomes in cell-free sample medium like urine, serum, and cell culture medium. Commercial kit is also available for isolating exosomes in cell-free medium using a fractionation approach by passing the medium over syringe filters (ExoMir TM , Bio Scientific Corporation, Austin, USA).
3) PRECIPITATION
A relatively easy, and instrument-free exosome isolation technique is precipitation, which often relies on the use of a precipitation reagent to alter the solubility or dispersibility of exosomes, thereby creating exosome-containing sediments available for retrieving using membrane filtration or lowspeed centrifugation. Several commercial exosome isolations kits, such as Exo-spin TM , and Invitrogen TM Total Exosome Isolation Reagent (Invitrogen, Carlsbad, USA) have been developed for isolating exosomes in common bodily fluids. Compared with other methods, precipitation eliminated the use of sophisticated instruments such as ultracentrifugation. However, the introducing of the precipitation reagent, most commonly with polyethylene glycol (PEG), run the risk of adding impurities to the isolated exosomes, which could potentially influence exosome biological activities. Recently, a non-PEG based exosome precipitation reagent was developed by Invent Biotechnologies (MINUTETM, Plymouth, USA). Combined with a saliva filter, exosomes can be readily precipitated from saliva, eliminating the saliva pre-treatment process [13] .
4) IMMUNE-AFFINITY CAPTURE
Since biomarkers such as CD9, CD63, EpCAM and CD81 are known to be found on the surface of exosomes, magnetic beads coated with a biomarker specific monoclonal antibody can then be used to isolate targeted exosomes. This method allows specific exosome subpopulations to be isolated and extracted with a higher recovery rate and purity compared with centrifugation, Also, this method is relatively easy to carry out, and does not require the use of dedicated instruments. However, this method involves further complication of having to elute the exosomes from magnetic beads before any downstream detection process [43] . Also, this method is only applicable for exosome subpopulations with known biomarkers, thus is not yet suited for all exosome types [44] . There are also commercial isolation kits available. ExoFACS TM (BioVision, San Francisco, USA) allows exosome isolation from various bodily fluids (plasma, urine, serum, saliva) and cell culture media. It uses magnetic beads for the overall capture of pre-isolated exosomes while uses lyophilized exosomes from cell culture supernatants or human biological fluids as the positive control. In addition, Saliva Exosome Purification Kit TM developed by Norgen Biotek Corp (Thorold, Canada) uses a proprietary resin/matrix that can be used for isolation and enrichment of intact saliva exosomes.
B. CONVENTIONAL EXOSOME DETECTION/ANALYSIS METHODS
After exosome isolation, methods including enzyme linked immunosorbent assay (ELISA), flow cytometry, fluorescence, tunable resistive pulse sensing (TRPS), nanoparticle tracking analysis (NTA), and dynamic light scattering (DLS) are the most used conventional methods for the quantification of analysis of exosomes. Since these methods have also been reviewed before [15] , they are only stated here briefly in reference to the microfluidic exosome analysis methods discussed in later sections.
1) ELISA & WESTERN BLOT
ELISA has been widely used for the detection of exosomes [45] - [47] . Generally, a multi-well plate is employed in an ELISA based approach. During operation, exosomes are first immobilized on the surface of individual wells. Next, a primary antibody that are specific to an exosomal biomarker is then introduced to the wells to form an antibody-antigen complex with the exosomes. Finally, an enzyme labeled (e.g., horseradish peroxidase, HRP) secondary antibody is used for specificity binding with the primary antibody, and a substrate (e.g., 3,3 ,5,5 -tetramethylbenzidine, TMB) is used for signal readout.
Similar to ELISA, western blot also relies on immunoaffinity between an antibody and the specific biomarker on the surface of exosomes (e.g., CD63). By identifying the presence of the biomarker during blotting, exosomes can be indirectly detected and quantified.
2) FLOW CYTOMETRY
Flow cytometry is known to be one of the most commonly used techniques for large quantity EVs detection due to its high throughput and ability to perform multiplex analysis [48] . In this technique, fluorescently labeled nanosized particles suspending in a sheath fluid is intersected with a laser beam. The resulting signal that is composed of scattering light and emitted fluorescence is recorded by dedicated detectors. However, due to limited sensitivity and resolution, the analysis of exosomes using conventional flow cytometers is rather limited and pending on the development of new technology [49] , [50] .
A specialized type of flow cytometry is fluorescenceactivated cell sorting (FACS) [51] . It allows the sorting of suspended nanosized particle according to their individual fluorescence characteristics. This is achieved by using specific antibodies functionalized with different fluorescent dyes. In recent years, FACS have widely been used for the analysis of exosomes [52] - [54] . Despite the usefulness, flow cytometry requires the use of highly sophisticated equipment, which may not be readily accessible in resource-limited settings.
3) TRPS
The TRPS method is based on the Coulter principle, which states the movement of non-conductive particles in an electrolyte solution can cause change in electrical impedance with respect to particle size, concentration and surface charge [55] . TRPS on the other hand can accurately determine the size, concentration and surface charge of EVs by measuring the impedance change or a resistive pulse signal when EVs are driven through a nanopore. The physical properties of the EVs can be obtained by analyzing magnitude, frequency and duration of the pulse signal [56] - [58] . VOLUME 7, 2019 4) NTA & DLS DLS and NTA methods rely on Brownian motion of particles to measure size distribution and concentration of nanoparticles [59] . DLS analyzes the intensity fluctuation of scattered light induced by Brownian motion of suspended or dissolved nanoparticles (i.e. exosomes) interacts with a laser light. NTA on the other hand, quantifies the size of nanoparticles by using the Stokes Einstein equation to calculate the hydrodynamic diameters of the nanoparticles when they are subjected to motion. NTA [60] - [62] and DLS [63] - [65] are widely used tools for analyzing the size distribution of exosomes due to its simplicity and ability to distinguish nanoparticles with a diameter range from 1 to 1000 nm. However, the results may not be accurate if the sample is heterogeneous or prone to aggregate. Also, the analysis throughput is relatively low.
Although the isolation and detection of exosomes have been successfully achieved using combinations of above-mentioned conventional methods. However, they often require the use of sophisticated instruments that are only accessible in centralized laboratories. In addition, conventional methods deal with isolation and analysis of exosomes separately, which further complicate the already lengthy process flow, and significantly increase the chance for contamination. Also, conventional methods usually excels at the isolation of a specific subpopulation of exosomes using known biomarkers, and it is therefore difficult to isolate an enriched population of exosomes among other nonspecific exosomes and EVs present in sample mixture [15] . Therefore, it is still challenging to implement exosome-based analysis as a routine diagnostic tool in clinical settings [11] .
IV. MICROFLUIDIC EXOSOMES ISOLATION AND ANALYSIS IN DIFFERENT BODILY FLUIDS
The advancement of microfluidics technologies offer new exosome isolation and detection techniques with great potential to overcome these limitations. Benefiting from small reagents volume, potential for multiplex operation, reduced analysis cost from chip mass-producing, and the ability to integrate different sensors and transducers with precise fluidic control, these microfluidic platforms have shown great promise for exosome analysis in clinical applications, exceling in reducing sample consumption, improving the analysis throughput, allowing disposable use to reduce crosscontamination and potentially enabling complete one step isolation-detection automation to improve the efficiency and the reliability of exosome isolation and detection. Since the late 2000, different microfluidics devices have been developed for exosome isolation and analysis. Some of the devices operate based on conventional principles such as size and affinity selection, others implement microfluidic approaches using as acoustic, electrophoretic and electromagnetic principles. We are going to analyze and compare the effectiveness and applicability of these approach for exosome isolation in different bodily fluids (serum, plasma, urine) in detail below.
A. EXOSOMES ISOLATION IN DIFFERENT BODILY FLUIDS 1) PLASMA
Since plasma is a highly complex and viscous fluid, isolation and detection of exosomes is rather technically challenging. The viscosity and high abundance of other non-specific proteins in plasma create significant obstacles in isolating pure exosomes.
Reátegui et al. developed a sensitive analytical microfluidic platform ( EV HB-Chip) that allows the isolation of tumor-specific exosome and other microvesicles from serum and plasma samples of glioblastoma multiforme (GBM) patients [66] . The platform used an immune-affinity based capture approach combined with chaotic passive mixing while featuring a layer of gelatin membrane functionalized with streptavidin-coated nanoparticles to increase the capture efficiency between the exosomes and antibody-coated surfaces. Using the plasma samples gathered from 11 GBM patients and 4 healthy donors as control, the method yielded a 59% of capture efficiency of tumor-specific EVs, a 94% tumor-EV specificity, This platform had the potential to address the limitations of the conventional isolation methods as it enabled a high tumor-specific EV isolation, had a relatively high throughput of 16.7 µL/min, and was available for mass production. The results showed in this work was very encouraging, however, the patient sample size in this study was still relatively small to draw any clinical conclusions. Also using immunocapture, Fang et al. developed a PDMS microfluidic device capable of capturing breast cancer-derived exosomes in plasma [67] . Their device consisted of dedicated microfluidic chambers and passive mixing channels to allow antibody-modified magnetic nanoparticles to capture an exosome specific protein. Due to the relatively large surface area of the nanoparticles, the authors achieved a higher capture efficiency compared with microchannel-based approaches. Although their method showed potential clinical values in both early-stage cancer detection and cancer molecular classification, the performances of the microfluidic platform including capture specificity and capture efficiency were not presented. Zhang et al. reported that graphene oxide (GO)-induced formation of a 3D nano-porous polydopamine (PDA) surface could improve the capture efficiency of cancer-derived exosomes in plasma samples [68] . The 3D-PDA coating was deposited layer-by-layer on the Y-shaped PDMS microposts within a microfluidic platform. The 3D-PDA coating featured a 3D porous structure that could substantially increase surface area to functionalize exosome specific antibodies to improve exosome capture efficiency. The platform was used to capture exosomes in clinical plasma samples collected form ovarian cancer patients. Zhao et al. from the same group later presented a PDMS based continuous-flow microfluidic platform for in situ isolation and multiplex detection of tumor-derived circulating exosomes in plasma [69] . This platform also relied on on-chip passive mixing and immunomagnetic assay to achieve exosome isolation. Using plasma samples from ovarian cancer patients and healthy individuals, the platform successfully achieved accurate discrimination of exosomes from cancer patients versus healthy individuals. The platform was characterized to have a sample analysis throughput of 1 µL/min and an exosome capture efficiency of 72%. Duani et al. reported a PDMS microfluidic platform that featured using inertial lift forces at finite Reynolds number to position exosome capturing beads due to the size differences with acellular contaminants [70] . Combing with bead-based exosome immunoaffinity capture off-chip, the platform allowed efficient exosome to capture at a much higher flow rate (70 µL/min) while effectively removing acellular contaminants. The work reported a 100% beads collection efficiency but did not state the exosome isolation efficiency. Similar microfluidic platforms utilizing immunoassay principles for on-chip capture of exosomes were also reported by He et al. [71] . This integrated microfluidic platform was used to study the clinical plasma gathered from non-small-cell lung cancer patients.
Besides immunoaffinity-based approaches, Cho et al. also presented an electro-migration method to effectively isolate EVs [72] . The method used a combination of pressure driven flow and induced electric field to drive the EVs and most of the proteins in the plasma who have a negative surface charge to migrate towards the anode while biomolecules with neutral or positive charges move along the flow or migrate towards the cathode. During the migration, a dialysis membrane filter with a 30 nm pore captures biomolecules with a diameter larger than the pore size while allow biomolecules smaller than the pore size to pass through, thereby completing the isolation. This method allowed a relatively fast EVs isolation (∼30 min) with a 65% EV recovery efficiency and an 84% plasma protein removal efficiency. However, using this method, exosomes cannot be directly isolated from other microvesicles.
Overall, microfluidic approaches have been successfully applied to the isolation of exosomes in blood plasma and yielded satisfactory results (Fig. 2 A-C) . However, due to the high viscosity, similar size microvesicles, and the existence of large amount of non-specific proteins in blood plasma, the isolation techniques are rather immunoaffinity-based approaches (Table 1) dominated. In addition, although microfluidic immunoaffinity capture significantly improved the isolation throughput and potentially also improved the isolation efficiency, similar to the conventional methods, they are not yet suited for all exosome types, and the need for antibody labeling may induce impurities during the downstream analysis.
2) SERUM
Exosomes in serum can also be used for assisting diagnosis and therapeutic decisions of various physiological conditions. Compared with plasma, serum is also highly complex but is far less viscous because of the necessary sample pre-treatment process. Nevertheless, the abundance of other non-specific proteins targets still presents a challenge in the extraction of exosomes. In serum, immunoaffinity capturing approaches were also the most commonly used among the developed microfluidic platforms. Work by Chen et al. was the first to use this approach in serum by immobilizing exosomespecific antibodies onto the inner surface of PDMS-based microchannels [73] . By selectively binding exosomes from serum samples of healthy and gliolastoma-confirmed patients to antibody coated surfaces, the work demonstrated the purification and extraction of exosomal RNA. In addition, this work was the first to employ herringbone structured micromixers to improve the capture efficiency. Using a similar approach, Kanwar et al. designed a microfluidic platform (ExoChip) that allowed the capture of exosomes using serum samples from healthy persons and pancreatic cancer patients [74] . The platform consisted series of alternatively placed circular chambers interconnected through straight narrow-cannels channels, and it captured exosomes using antibodies that were functionalized onto the inner surface of PDMS. The geometrical design allowed changing fluid velocity during sample introduction to increase retention time for exosomes to interact with the functionalized antibody. However, releasing the captured exosomes intact and label-free for downstream analysis remained a challenge. Xu et al. developed a microfluidic platform (ExoPCD-chip) to capture tumor-derived exosomes from blood serum samples of liver cancer patients [75] . Different from commonly employed antibody-antigen capture approaches, the authors used Tim4 functionalized magnetic beads to bind with phosphatidylserine (PS) expressed on exosome membrane. The affinity method enhanced exosome capture efficiency and enabled the detachment of exosomes under mild elution conditions, facilitating downstream analysis. In addition, the microdevice was integrated with staggered Y-shaped micropillars mixing pattern to create anisotropic flow to increase the opportunity of collisions between the magnetic beads and exosomes. Hisey et al. used a modified protocol that can also achieve the capture and release of tumor-derived exosomes in a microfluidic platform from serum samples (10X diluted) of ovarian cancer patients [76] . Different from using magnetic beads for affinity capture, antibody was functionalized directly on the inner surface of the PDMS channel. Herringbone microstructures were also integrated in the microchannel to improve the capture efficiency. In addition, the authors discovered that the antibody-antigen affinity bonding could be eluted by introducing glycine-HCl buffer at a pH of 2.2. Based on their study, the eluted exosomes remain intact, label-free and allowed to be used on precise downstream characterization techniques design for intact exosomes, such as flow cytometry. Moreover, by eliminating the use of magnetic beads, this approach enabled a relative quick analysis time. However, if the platform intended to be reusable, exosome capture efficiency after a few uses needed to be quantified since the introduction of buffer may affect the antibody activity. Immuno-affinity could also be paired with droplet microfluidics to achieve single-exosome level isolation. Liu et al. developed a microfluidic platform featuring the encapsulate of exosome capturing magnetic beads so that downstream analysis could be performed at a single-exosome level [77] .
Using their platform, 40 µm diameter mineral oil droplets was generated to encapsulate beads and fluorescein-di-β-Dgalactopyranoside (FDG) substrate. The controlled droplet size also ensured most droplets contain no beads or one bead. Immunoaffinity isolation of exosomes was implemented on other microfluidic platforms. Chen at el. developed a cost-effective, robust, easy-to-use paper based immunoaffinity platform for separating subsets of EVs [78] . Paper based microfluidic platforms were known to be available for pointof-care, disposable use, the authors immobilized antibodies on porous cellulose membranes via chemical conjugation to capture EVs. The platform was used in the analysis of serum samples from healthy donors and aqueous humor samples from patients. Although effective, the antibody functionalization process was rather complex, which defeated the purpose of using a disposable paper chip. Also, since the cellulose fiber structure could desorb 40% or more antibody molecules upon the introduction of blood samples, the capture efficiency of EVs was rather limited.
Chen et al. were the first to combine immunoaffinity capture with size exclusion for high efficient exosome capture in serum by developing a ZnO nanowire coated 3D scaffold chip device [79] . The platform was prepared by hydrothermally growing a ZnO nanowire mesh from ZnO nanocrystal seeding layer-coated PDMS scaffolds. To capture exosomes in patient serum samples, antibody specific to a generic exosome surface biomarker was functionalized on the ZnO nanowire. Due to the large surface area of the nanowire structure, more antibodies were immobilized per area to improve the overall exosome capture efficiency. Also, during sample introduction, due to inherent ZnO meshing structure, the nanowires exerted size exclusion-like effect and induced chaotic mixing at a high flow rate (10 µL/min) to further improve the capture efficiency.
Another problem with existing exosome isolation techniques was that the need to use labels often introduced impurities that could potentially compromise the accuracy of downstream analyses. Liu et al. developed a viscoelastic microfluidic system that enabled the separation of exosomes from other large EVs in fetal bovine serum [80] . In their work, a heavily diluted poly-oxyethylene (PEO) solution was used as a viscoelastic sheath fluid to generate elastic lift forces to control the lateral positions of different EVs according to their size differences. By optimizing microchannel geometry, medium elasticity, and flow condition using both analytical analysis and numerical simulation, the platform allowed a fast migration of larger EVs to the centerline of the microchannel and a slower migration of smaller EVs to the sides of the microchannel. This approach enabled exosomes (<200 nm) to be isolated with a high recover rate of >80% and a high purity of >90% in serum. Since the approach did not require any sample pretreatment process, the overall analysis time was significantly reduced. Also, the intact, label-free exosomes were directly collected at the platform outlet. However, no patient sample was studied in this report to validate this approach.
Active exosome isolation methods such as electrophoresis could also be implemented in microfluidics. Marczak et al. developed a microfluidic platform that could simultaneously isolate and preconcentrate exosomes using a local transverse electric field generated by an ion-depleting ion-selective membrane [81] . The membrane produced a local ion depletion zone that spanned across the flowing steam and into the gel to generate a high transverse field, without introducing excess temperature increase and bubble formation. The electric field drove particles toward the negatively charged membrane while the agarose gel filtered out any larger particles due to their pore size to complete the isolation. On the other hand, smaller biomolecules such as exosomes approached the membrane, they became enriched near the surface of the membrane. This approach was applicable to isolation in blood serum samples with a 60 to 80% capture efficiency and achieved an enriched concentration factor of 15 after introducing sample fluid continuously for 10 mins at a rate of approximately 3 µ L/min. The platform also had potential to integrate with on-chip SAW based modules and DNA probe-functionalized ion-selective membrane to lyse exosomes and detect miRNA Approaches that are applicable to isolation of exosomes in serum are summarized in Table. 2. Although immunoaffinity approaches are still preferred in serum samples, more approaches such as viscoelastic flow presented a promising label-free alternative for exosome isolation. In addition, advancements for detaching the captured exosomes have been made, which allows direct analysis of intact exosomes (Fig. 3 A-C) .
3) OTHER BODILY FLUIDS
Microfluidic based approaches have also been applied to the isolation of exosomes in other bodily fluids such as urine, whole blood and ascites fluid. Urinary EVs including exosomes, microvesicles, and apoptotic bodies shed from entire genitourinary epithelium including but not limited to kidney, urothelium, prostate, and bladder [82] . Therefore, the isolation and analysis urinary exosomes have great potential in realizing noninvasive early disease diagnoses. However, because the concentration of entire EVs population in urine is extremely low (<0.01 volume %) to use conventional methods [83] , the isolation of EVs in urine is still in the early developmental stage.
Yasui et al. took advantage of the inherent negative surface charge of EVs and developed a zinc oxide based microfluidic platform for the isolation of EVs and extraction of EV-encapsulated microRNAs (miRNAs) [83] . The authors prepared zinc oxide and aluminum oxide (ZnO/Al 2 O 3 ) coreshell nanowires by covering the ZnO nanowire with a 10-nm-thick Al 2 O 3 layer. The nanowires were then integrated in the channels of a PDMS-based microfluidic device (Fig. 4A) . Because of the isoelectric point of Al 2 O 3 , the nanowires exhibited a slight positively charged surface. Thus, EVs and urinary free-floating objects with diameters up to 200 nm could be collected due to electrostatic interactions with a 99% collection efficiency. Compared with conventional methods, this approach offered high collection efficiency, high collectability, a high-throughput (25 µL/min). However, this method had a relatively low sample selectivity as it collected EVs or other objects with a diameter smaller than 200 nm and a negative surface charge. Another approach used in exosomes isolations in urine was membrane filtration. Liang et al. designed a double membrane filtration microfluidic device that was able to isolate EVs with a size range of 30-200 nm [84] . Based on the size-exclusion principle, two polycarbonate membranes with pores sizes of 200 and 30 nm were assembled to form a sample chamber, an isolation chamber, and a waste chamber. During isolation, particles larger than 200 nm were kept in the sample chamber, particles smaller than 200 nm but larger than 30 nm were able to enter the isolation chamber and particles smaller than 30 nm were disposed in the waste chamber. The platform achieved a relatively high EVs recover rate for isolating EVs in urine samples collected form healthy people and bladder cancer patients. Around the same time, Woo et al. developed an integrated centrifugal microfluidic platform (Exodisc) that was used for automatic isolation and enrichment of EVs [85] . Also based on membrane filtration, the Exodisc consisted of two independent filtrations units that allowed parallel processing of two different samples. Each filtration unit consisted of microfluidic chambers with connecting channels and diaphragm valves for active flow control. Because the Exodisc operated fully automatically by spinning at 3000 rpm, the isolation of EVs was completed with a relatively high throughput (34 µL/min). In addition, the approach enabled high recovery rates of intact EVs (>95% recovery of EVs) in urine samples of bladder cancer patients and healthy donors. However, a major limitation of membrane filtrationbased methods overall was the relatively low sample selectivity, which could limit the purity of isolated EVs.
Exosome isolation from whole blood is considered as the most difficult since cells and other significantly larger debris have to be removed beforehand. Davies et al. employed photopatterned porous polymer monoliths as membranes to demonstrate two sized-based membrane filtration approaches, pressure-driven and electrophoretic. By properly tuning the porous properties of the membranes, both approaches were capable of performing direct isolation and extraction of EVs from mouse whole blood by allowing particles smaller than the pore size to pass through for further analysis while blocking cells and other larger debris [86] . The pressure-driven mode yielded a higher capture efficiency. However, the pressure-driven mode was susceptible to clogging after a few uses. The electrophoretic mode effectively addressed the clogging while enabled a higher extracted EVs purity and a higher throughput.
Based on hydrophoresis, Kim et al. developed a motorized smart pipette integrated with a feedback controller and a polydimethylsiloxane (PDMS) separator that composed of grooved microchannels with periodic slanted ridges to separate plasma from whole blood (Fig. 4C) . In this work [87] , the motorized pipette and the feedback controlled generated a stable pressure-driven flow to allow blood to flow through the separator. After an exosome count of 7.3 × 10 11 was spiked in the whole blood sample, the method yielded a 90.5±5.2% exosome recovery efficiency with a high flow rate of 422.3 µL/min. This system is portable, easy to use, and cost-effective. However, further tests were needed to assess the purity of the isolated exosomes.
By integrating acoustics and microfluidics, Wu et al. developed a microfluidic platform that was capable of directly isolating exosomes from whole blood [88] . The platform was composed of a cell-remove module and an exosome-isolation module. Both modules relied on the formation of sequential surface acoustic wave (SAW) fields, which were built by on-chip interdigital transducers (Fig. 4B) . During operation, the cell removal module first separated EVs from the whole blood by removing cells and larger debris. Next, the exosome-isolation module further purified the separated EVs by removing the other subgroups basing on size differences. This technique was fully automated, did not require any form of sample preprocessing, and was label-free. The platform demonstrated the isolation of bioparticles larger than 150 nm from exosomes in blood samples. In addition, the authors stated that the platform was also applicable for the separation of exosomes in other common bodily fluids as well. The potential wide applications of this approach are very encouraging; however, more clinical sample need to be studied to verify this approach.
Exosomes isolated from ascites fluid were also known to have diagnostic values for ovarian cancer patients. Im et al. developed a surface plasmon resonance platform nPLEX that replied on immunoaffinity capture approach for the isolation of exosomes in ascites fluid [89] . Exosome-specific antibodies were conjugated to the PEG-functionalized gold surface in ascites fluid of healthy donors and ovarian cancer patients. Since the isolation and capture of exosomes occurred directly on the gold substrate, there was no need to design complicated microfluidic channel structures to accommodate large number of exosomes in biological samples.
Approaches that are applicable to isolation of EVs in urine, whole blood and ascites fluid are summarized in Table. 3 below. Overall, these approaches have demonstrated improvements in capture efficiency, analysis throughput and in some cases, specificity. However, it is worth noting that microfluidic immunoaffinity capture approaches have yet to be applied to isolate exosomes in urine. Since the urinary composition is simpler than the blood, so that most of the microfluidic immunoaffinity approaches described above should also be directly applicable. Also, although current microfluidic physical isolation techniques such as double filtration can conduct unbiased capture of all urinary EVs within the size range, exosomes subpopulation have yet to be isolated.
B. EXOSOMES DETECTION AND ANALYSIS IN DIFFERENT BODILY FLUIDS
An important aspect of using microfluidic approaches is that the potential to integrate exosome isolation and analysis onto the same chip. However, some of the above-mentioned techniques are designed solely for exosome isolation, and thus would require the use of a conventional methods for exosome downstream analysis. To achieve the full potential of microfluidic platforms, different approaches have been successfully developed to enable sensitive detection of exosomes. In the following sessions, we are going to summarize these chip-based exosome analysis methods, in particular those integrate the functionalities of exosome isolation and quantification in a platform and compare the utility of these methods using reported LOD values.
1) PLASMA
He et al. developed an integrated microfluidic platform (Fig 5C) for the isolation and phenotyping of exosome subpopulations in blood plasma samples [71] . The approach was based on magnetic exosome capture and chemifluorescence detection. The microfluidic platform used a cascading microchannel design to perform exosome isolation and enrichment, chemical lysis and immune-precipitation, chemifluorescence assisted immunoassay sequentially. The utility of this platform was demonstrated by quantitative exosome intravesicular protein analysis, specifically type 1 insulin growth factor receptor (IGF-1R) and phosphorylated IGF-1R (p-IGF-1R), from non-small-cell lung cancer (NSCLC) derived exosomes. Although the analysis principle used in 45090 VOLUME 7, 2019 this work is well-established, compared with conventional methods, the microfluidic approach showed a significant increase in sensitivity (0.281 pg mL −1 ) while reducing the analysis time (< 1 hr) and sample volume (30 µL). A similar microfluidic platform (Fig. 5B) developed by Fang et al. used a combination of exosome immunoaffinity capture and immunofluorescence staining approach to quantify EpCAM(+) and HER2(+) exosomes on chip using plasma samples of breast cancer-derived patients and healthy donors [67] . Also relying on the integration of immunoaffinity capturing and multiplexed immunoassay, Zhao et al. developed a microfluidic platform (Fig. 5A ) that was capable of performing on-chip multiplexed exosomal marker detection [69] . This was enabled by continuously flowing a mixture of three probing antibodies (anti CA-125, anti-CD-24 and anti EpCAM) labeled with different fluorescent dyes (A488, A550, and A633) in the microchannels to bind with the magnetic beads captured exosomes. This approach was able to quantify ovarian cancer-derived exosomes in patient plasma samples with a LOD of 750 particles per µL, a 20 µL sample volume and a 40 min analysis time. In addition, this approach allowed simultaneous identification of multiple cancer-derived exosome biomarkers, which improves accuracy for potential disease early diagnostics. Zhang et al. on other hand developed an integrated microfluidic platform that was capable of performing ultrasensitive exosome quantification in plasma samples using a layer of GO-PDA coating [68] . The ultrahigh sensitivity was achieved by a combination of improved capture efficiency and reduced non-specific exosome binding, both of which were due to the addition of GO-PDA significantly increased the available sites to immobilize exosome specific antibodies in microfluidic channels. This work demonstrated on-chip quantification of ovarian cancer-derived exosomes with a plasma sample volume of 2 µL (corresponds to a total analysis time of under 10 min) and a LOD of 50 exosomes per µL, despite using the same on-chip fluorescence immunoassay quantification principle. The work showed great potential in using microfluidics for high-throughput screening of clinical samples, however, a more systematic clinical evaluation was required to further validate this approach. At last, Duani et al. reported an integrated PDMS microfluidic platform that combined immunoaffinity magnetic beads capture, inertial lift force size selection and inline fluorescence detection via flow cytometry to quantify exosomes in cell culture supernatants and blood plasma samples at a relatively high flow rate of 70 µL/min, an equivalent analysis time of a few minutes [70] .
Overall, the microfluidic platforms that have been developed for quantification and analysis of exosomes in blood plasma samples uses immunoaffinity based detection approaches (Table 4) . These advancements demonstrated the great potential of using such platforms for integrated analysis in clinical setting, as some platform have achieved the detection limit of several hundred exosomes per microliter and enabled a much faster analysis time of less than an hour. However, immunoaffinity based detection methods are limited to the quantification of exosomes with known target biomarkers, which may result in missing of biomolecular information. 
2) SERUM
The ExoPCD chip (Fig. 6B) developed by Xu et al. used a label-free and immobilization-free on-chip aptameric electrochemical detection approach to quantify exosomes [75] . The approach was based on the interaction among a CD63 apatmer, captured CD63-positve exosomes, and hemin to form a signal reporter G-quadruplex, which acted as the NADH oxidase and produced hydrogen peroxide on the surface of ITO electrodes for signal transduction. The chip was used to detect tumor-derived exosomes from 10% diluted blood serum samples (30 µL) of liver cancer patients and demonstrated a LOD of 23 particles/µ L, a wide linear detection range of 598 to 5.98 × 10 5 particles/µL, and a total analysis time of 3.5 h. Because the PS-Tim4 affinity capture method allowed exosome detachment, besides on-chip electrochemical detection methods, conventional exosome detection methods such as flow cytometry were also compatible with the ExoPCD chip.
In addition, the aptamer could be altered conveniently to recognize other exosome subpopulations expressing different surface proteins
Another label-free exosome quantification approach was microfluidic-based Surface Plasmon Resonance (SPR). Sina et al. used this method to quantify a tumor-derived exosome subpopulation from breast cancer patient serum [90] . The method worked by first capturing a bulk exosome population using a generic exosome surface biomarker functionalized on a SPR substrate. Then, a secondary antibody was introduced to the SPR chip to selectively bind with a specific subpopulation of exosomes. The binding was associated to a mass increase at the sensing surface over time, which generated a local change in refractive index and enabled the real-time and label-free concentration readout of the exosome subpopulation. The utility of the microfluidic SPR platform was demonstrated by the quantification of HER2(+) exo- somes from serum samples of breast cancer patients. with a LOD of 2070 particles/µL and a linear dynamic range of 2.1 − −33.4 × 10 3 particles/µL.
Immunoassay can also be integrated with droplets to enhance the LOD. Liu et al. developed a droplet based singleexosome-counting immunoassay (ExoELISA) chip (Fig. 6C ) that offered improved quantification LOD and specificity for exosomes with specific protein biomarkers [77] . The onchip droplet immunoassay was achieved by first immobilizing an enzymatic reporter tagged detection antibody onto the exosome-captured magnetic beads. The beads and the enzymatic FDG substrate were next encapsulated at the same time into droplets. By optimizing the chip geometry and flow condition, the ExoELISA chip was able to ensure most droplets contain no more than one bead. Finally, the substrate was catalyzed by the enzyme to emit fluorescein within the droplet, thereby allowing sensitive exosome concentration quantification at an enhanced LOD of 10 particles/µL.
Chen et al. used on-chip paper-based colorimetric immunoassay to quantify bulk EVs populations in undiluted serum samples [78] . After the EVs were isolated on the antibody-immobilized (anti-CD63) paper surface, another antibody (anti-CD9) also specific to a generic surface biomarker of bulk EV populations and HRP-linked secondary antibody were introduced to the chip as well sequentially. Finally, colorimetric substrate containing hydrogen peroxide and TMB were added to the chip to induce the paper color change. However, the LOD and linear dynamic range of the approach were not reported in this work. Same colorimetric immunoassay principle was used in the ZnO-chip (Fig. 6A) developed by Chen et al. as well [79] . In their work, a quantification LOD of 2.2 × 10 4 particles/µL and a linear dynamic range of 2.2 × 10 5 − 2.2 × 10 7 particles/µL was obtained. Although not as sensitive as some of the reported work, colorimetric approach is a fast, direct visualization and cost-effective detection method that do not need sophisticated analytical tool.
The ExoChip developed by Kanwar et al. [74] used a fluorescent carbocyanine dye (DiO) to stain the immobilized exosomes, and the concentrations levels of bulk exosomes was visualized and quantified on-chip using standard analytical tools such as a plate reader. The utility of the platform was demonstrated by quantifying exosomes in serum samples gather from healthy donors and pancreatic cancer patients with a fluorescence detection limit of 0.5 pM.
Overall, different approaches have been developed for microfluidic detection of exosomes including electrochemical, SPR, colorimetric, fluorescence and droplet-based immunoassay (Table 5 ). These approaches in general improve detection sensitivity, reduce sample consumption and analysis time. However, it is worth noting that the enhanced exosome quantification LOD of approximately 10 exosomes/µL demonstrate by Liu et al. shows great potential for detecting extremely low abundance exosomes in a clinical setting. Also, the simplistic, potential instrument-free colorimetric immunoassay detection approaches have great potential to be used in POC applications.
3) OTHER BODILY FLUIDS
Microfluidic based approaches have also been applied to the quantification of overall exosome levels as well as exosome subpopulations in other bodily fluids such as urine, whole blood and ascites fluid. The quantification of exosomes in urine is inherently difficult due to the extremely diluted concentration of exosome (<0.01 volume %). Therefore, besides isolation, exosomes much also be enriched before the quantification. Liang et al. developed a double membrane filtration microfluidic platform (Fig. 7C ) that was capable of quantifying general EVs population using an on-chip colorimetric immunoassay approach [84] . After isolation through the double filter membrane based on size exclusion principle, bulk population of EVs with a size between 30-200 nm were kept in the isolation chamber. For this method, sample solution was required to be introduced to the microfluidic platform continuously so that EVs in the isolation chamber (165 µL) can be enriched. The enriched EVs were then labeled with a primary antibody, and the resulting complex was subsequently interacted with streptavidin-HRP as well as TMB to complete the colorimetric assay. Another microfluidic platform (Exodisc) (Fig. 7B ) based on the same double-filter size exclusion principle was developed by Woo et al. to achieve fully automatic isolation, enrichment and quantification of EVs [85] . Because of the filter pore size optimization and automatic operation, the Exodisc was able to retrieve a 3.9-fold higher number of EVs compared with conventional ultracentrifugation method and a commercial isolation kit (analyzed by NTA). On-chip colorimetric immunoassay was also applied for the quantification of retrieved EVs.
Beside exosome detection in urine, Taller et al. demonstrated a microfluidic platform (Fig. 7A ) that was capable of performing SAW lysis of exosomes and a dedicated nano-membrane sensor was used for miRNA detection [91] . Without introducing any chemical lysates, exosomes from cell culture medium were lysed by a combination of acoustic radiation force and the dielectrophoretic force, which were generated by scattered sound waves induced acoustic pressure in the liquid bulk and the electromechanical coupling within the SAW induced electric field. After lysis, the sample reagent was collected from the outlet and subsequently introduced to a separate ion-exchange nanomembrane sensor for the detection of miRNA on-chip. Combining with the work from the same group that used dielectrophoretic method to isolate exosomes in serum, a highly integrated device could potentially be developed to achieve isolation, detection and identification of exosomal RNA in a label-free manner. However, such a device has yet to be developed.
An alternative label-free detection approach is via SPR. Unlike the conventional SRP reflection approach, Im et al. developed a transmission detection approach for analyzing cancer biomarkers from exosomes that are present in ascetic fluid from ovarian cancer and healthy donors [89] .
The approach is implemented in a microfluidic chip (nPLEX) consisting of PDMS-based fluidic channels and periodic nanohole arrays incorporated metal film. The nanohole arrays are functionalized with affinity ligands for various exosomal surface biomarkers for specific capture. Due to the small size of the nanohole sensing units (100 nm) and a compact collinear optical setup, the nPLEX chip offers an unprecedented quantification throughput of 1089 parallel measurements per experimentation and is readily scalable to adapting 10 5 parallel measurements. The nPLEX chip is characterized to have a LOD of 670 aM, although it was demonstrated only with exosome-rich samples (> 10 9 exosomes per mL).
Overall, the microfluidic platforms that have been developed for quantification of overall exosomes levels, detection of exosome subpopulations and analysis of exosomal cargo (miRNA) in other bodily fluids including urine, ascetic fluid, and rare cell media (Table 6 ). Benefitting from these advancements, multiplex detections can now be achieved for both overall exosomal level and subpopulation with minimal sample volume required. This holds tremendous clinical value for exosome to be used in early disease diagnosis and prognosis.
V. CONCLUSION AND OUTLOOK
Ever since the first discover of exosomes and other extracellular microvesicles, their potential therapeutic values as biomarkers in emerging diagnostics approaches have gained tremendous interests. However, the established methods that hindered by their isolation purity, efficiency and detection accuracy still have rather limited clinical values. Therefore, since the first report of using microfluidic based approach for isolation of exosomes, research have oriented towards the development of highly specific, sensitive, integrated systems with high-throughput. In this review, we first briefly summarized the established exosome isolation and detection methods. Then we focused on the recent progress made in using microfluidic-based innovative approaches to address these said limitations. Since disease-specific exosomes can be found at different body locations as well as in different concentrations, the selection of isolation and detection approaches could significantly affect the outcome of the analysis. Therefore, we choose to sort these approaches by their utility in different bodily fluids instead of their working principle. In the process, we have identified several recent advances that have successfully integrated the functionalities of exosomes isolation, concentration and detection onto a single microfluidic lab-on-a-chip platform. Such integration demonstrated real potential of using these technologies for clinical practice. However, despite the progress, there still lacks all-around microfluidic based exosome isolation and detection techniques, as the field is still in its infancy. Specifically, immuno-affinity isolation methods are highly disease-specific, especially as the recent implementation of nanomaterial further improved upon that. However, they rely heavily on the development of antibodies that must be both specific to the target of interest and do not participate in the downstream analysis. Since the antibody developmental efforts have been primarily focused for blood-based analysis, it was not to our surprise that the exosome isolation in blood-based media almost exclusively used immune-affinity technique. As for the other bodily fluids in which the biomolecule compositions are far less complicated such as urine, sized-based exosome isolation techniques, both passive or active have been developed. Compared with immuneaffinity techniques, size-based methods are label free, which significantly reduces the number of sample processing steps priori to analysis and does not induce potential impurities during analysis. However, passive size-based techniques such as membrane filtration have a rather poor selection resolution. Although active techniques can potentially solve this problem, whether the transducer induced fields affect the properties of exosomes remain unknown. Different from the exosome isolation techniques, the review shows microfluidic exosome detection techniques are applicable to exosomes in all bodily fluids.
Knowing the current research status, now we briefly discuss the possible future directions. The ultimate goal for exosome research is to aid clinical diagnostics and therapeutics in a low cost, reliable and minimal invasive manner. Although current research has demonstrated the ability to perform integrated exosome isolation and quantification on LOC platforms, diagnostics and therapeutics often require downstream analysis of exosomes beyond that. Therefore, we either can identify more disease-specific exosomal biomarkers or develop integrated microfluidic exosomal cargo analysis techniques. The former is more of a biological effort and latter requires the integration of exosome isolation, lysis, and cargo analysis techniques.
Although not yet integrated, the work by Taller et al. is a very good example of how the lysis and cargo analysis can be achieved. In addition, to achieve minimal invasive diagnostics, the isolation and analysis of exosomes in easily accessible body fluids such as urine, sweat, and saliva are of great importance. Out of them, sweat and saliva are more attractive due to their constant regenerative nature and it exhibits various extends of plasma. Specifically, based on a recent report, 1062 proteins were identified from sweat exosomes and 997 of them are proteins that have not been reported previously, which suggests the possibility of using sweat exosomes as a source of biomarkers for disease such as cystic fibrosis, diabetes, and schizophrenias [92] . However, since the concentration of sweat and salivary exosome are significantly lower than that in blood, works on microfluidic based saliva and sweat exosome isolation/detection have yet to be published. So the development of microfluidic-based salivary and sweat exosomes isolation/analysis techniques are another field worth of pursuing. Given the significance of exosomes research and considerable amount of resource and efforts invested, we expect next-generation microfluidic platforms that can routinely perform not only isolating, subtyping, and quantifying the total population of exosomes, but also analyzing the contents of exosomes to facilitate both basic VOLUME 7, 2019 research and clinical applications to be developed in the near future. 
